文献速递临床试验与 GCP基础与转化研究

青春双歧杆菌治疗伴Modic改变的慢性下腰痛患者:多中心、随机、安慰剂对照试验的研究方案

Bifidobacterium treatment for chronic low back pain in patients with Modic changes: study protocol for a multicenter, randomized, placebo-controlled trial.
PubMed 文献 · Trials · 2025-09-24

这项多中心、双盲、随机、安慰剂对照试验将在中国四家医院开展,比较口服青春双歧杆菌与安慰剂在伴Modic I型或II型的慢性下腰痛患者中的疗效。受试者每日两次用药,持续三个月;主要结局为治疗后3、6、12个月简体中文版Roland-Morris功能障碍问卷评分变化。

要点

  • 研究纳入伴Modic I型或II型的慢性下腰痛患者,随机接受青春双歧杆菌或安慰剂治疗三个月。
  • 主要结局为治疗后3、6、12个月简体中文版Roland-Morris功能障碍问卷评分变化。
  • 次要结局包括DASS-21评分、MRI影像、骨密度测量和血清生物标志物分析变化。

核心结论

  • 该研究将为青春双歧杆菌治疗伴Modic改变的慢性下腰痛提供治疗潜力方面的见解,可能为这一常见且致残性疾病提供新方法。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照试验,将在中国四家医院开展。
  • 比较口服青春双歧杆菌与安慰剂的疗效,受试者每日两次用药,持续三个月。
  • 研究对象为伴Modic I型或II型的慢性下腰痛患者,符合条件者随机分配接受青春双歧杆菌或安慰剂治疗三个月。

关键数值与推荐

  • 主要结局为治疗后3、6、12个月简体中文版Roland-Morris功能障碍问卷评分变化。
  • 次要结局包括DASS-21评分、MRI影像、骨密度测量和血清生物标志物分析的变化。
  • 试验已在中国临床试验注册中心注册,注册号为ChiCTR2400088577,注册日期为8月21日,为前瞻性注册。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low back pain (LBP) is a major global health issue, affecting approximately two-thirds of the population at some point in their lives. Modic changes (MCs) in the vertebral endplates, as observed on MRI, are recognized contributors to LBP and may be linked to advanced stages of intervertebral disc degeneration (IDD). Prior research has shown a decrease in the genus Bifidobacterium in the endplate cartilage of patients with IDD and concurrent MCs. The potential link between reduced Bifidobacterium levels and MC-related LBP remains unclear. METHODS: This multicenter, double-blinded, randomized, placebo-controlled trial will be conducted at four hospitals in China, comparing the efficacy of orally administered Bifidobacterium adolescentis (BA) with that of a placebo. Participants will receive the treatment twice daily for a duration of three months. The study targets patients with chronic low back pain (LBP) and Modic type I or II. Eligible patients will be randomly assigned to receive either Bifidobacterium adolescentis or a placebo for three months. The primary outcome will be the change in the Simplified Chinese Roland-Morris Disability Questionnaire (SCRMDQ) score at 3, 6, and 12 months post-treatment. Secondary outcomes include changes in DASS-21 scores, MRI imaging, bone density measurements, and serum biomarker analysis. DISCUSSION: This study will provide valuable insights into the therapeutic potential of Bifidobacterium adolescentis in managing chronic LBP associated with Modic changes, potentially offering a novel approach to treating this common and debilitating condition. TRIAL REGISTRATION: The trial has been registered with China Clinical Trial Registry, under the registration number ChiCTR2400088577. Registered on 21 August. The study was prospectively registered.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nian S, Li C, Li N, et al. Bifidobacterium treatment for chronic low back pain in patients with Modic changes: study protocol for a multicenter, randomized, placebo-controlled trial. Trials. 2025. PMID: 40993700. doi:10.1186/s13063-025-09084-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。